New combo therapy aims to outsmart 'Cold' rectal tumors
NCT ID NCT07026422
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II trial tests whether adding a dual immunotherapy drug (iparomlimab/tuvonralimab) to standard chemoradiotherapy can improve outcomes for patients with locally advanced rectal cancer that has a specific genetic profile (pMMR/MSS), which usually does not respond to immunotherapy alone. The study plans to enroll 54 participants and will measure the rate of complete tumor disappearance. The goal is to see if this combination can turn 'immune-cold' tumors into 'hot' ones that respond better to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iparomlimab/tuvonralimab (a dual immunotherapy drug) combined with chemoradiotherapy
What this could lead to
If successful, this could offer a new treatment option for patients with a common type of rectal cancer that typically does not respond well to immunotherapy alone.
What could go wrong
This is an early, small Phase II trial with only 54 participants, so results may not apply broadly. The combination therapy may cause side effects from both immunotherapy and chemoradiotherapy, and it is not yet known if it will improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Cancer Hospital and Institute
RECRUITINGJinan, Shandong, 250000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••